A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease; Dementia; Down syndrome; Lewy body disease; Vascular dementia
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 12 Mar 2015 Status changed from recruiting to completed.
- 21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Aug 2014 New trial record